|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2011094198A1
(en)
*
|
2010-01-28 |
2011-08-04 |
The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
JP6198278B2
(ja)
*
|
2011-09-08 |
2017-09-20 |
ユニキュアー アイピー ビー．ブイ． |
Ａａｖ調製物からの混入ウイルスの除去
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
|
AU2014354839B2
(en)
|
2013-11-26 |
2020-06-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors for treatment of glycogen storage disease
|
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
PL3628334T3
(pl)
*
|
2014-03-21 |
2023-12-18 |
Genzyme Corporation |
Terapia genowa w retinopatii barwnikowej
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
HUE046643T2
(hu)
*
|
2014-11-28 |
2021-11-29 |
Uniqure Ip Bv |
DNS szennyezõdések parvovirális virionokat tartalmazó készítményben
|
|
WO2016106303A1
(en)
|
2014-12-23 |
2016-06-30 |
THE UNITED STATES OF AMERICA, as representd by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Adeno-associated virus vectors encoding modified g6pc and uses thereof
|
|
US9862936B2
(en)
|
2015-01-13 |
2018-01-09 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
WO2016137949A1
(en)
*
|
2015-02-23 |
2016-09-01 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3283126B1
(en)
|
2015-04-16 |
2019-11-06 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
ES2856936T3
(es)
|
2015-04-23 |
2021-09-28 |
Univ Washington State |
Suministro del gen Smad7 como un agente terapéutico
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
AU2016366560A1
(en)
*
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
ES2934848T3
(es)
*
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
US11028372B2
(en)
*
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
BR112018012235A2
(pt)
|
2015-12-18 |
2018-12-04 |
Sangamo Therapeutics Inc |
rompimento alvejado do receptor de células de mhc
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
KR20180101442A
(ko)
|
2016-02-02 |
2018-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물
|
|
EP3411484B1
(en)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
LT3436051T
(lt)
*
|
2016-03-31 |
2021-11-25 |
Spark Therapeutics, Inc. |
Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
|
IL301963A
(en)
*
|
2016-07-21 |
2023-06-01 |
Spark Therapeutics Inc |
Scalable High Recovery Methods for High-Throughput Recombinant Adeno-Associated Viral Vector Production and Recombinant Adeno-Associated Viral Vectors Made So
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
|
|
EP3995574A1
(en)
|
2016-08-24 |
2022-05-11 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CA3040288A1
(en)
*
|
2016-11-04 |
2018-07-12 |
Baxalta Incorporated |
Adeno-associated virus purification methods
|
|
EP3321357A1
(en)
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
|
CA3050917A1
(en)
|
2017-01-30 |
2018-08-02 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant virus vectors for the treatment of glycogen storage disease
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
WO2018226887A1
(en)
|
2017-06-07 |
2018-12-13 |
Spark Therapeutics, Inc. |
ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
|
|
PE20200737A1
(es)
*
|
2017-06-30 |
2020-07-23 |
Spark Therapeutics Inc |
Metodos de purificacion de columna de vector aav
|
|
AU2018313167A1
(en)
|
2017-08-08 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
US11926653B2
(en)
|
2017-10-20 |
2024-03-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for NT-3 gene therapy
|
|
WO2019094253A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Avexis Inc. |
Means and method for preparing viral vectors and uses of same
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US12312416B2
(en)
|
2018-02-06 |
2025-05-27 |
Seattle Children's Hospital |
Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
AU2019225174B2
(en)
|
2018-02-23 |
2025-11-20 |
Endocyte, Inc. |
Sequencing method for CAR T cell therapy
|
|
EP3758736B1
(en)
|
2018-03-02 |
2024-05-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Il-34 for use in a method of treating retinal inflammation and neurodegeneration
|
|
WO2019195729A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Nightstarx Ltd. |
Aav compositions, methods of making and methods of use
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
EP3801638A1
(en)
|
2018-06-08 |
2021-04-14 |
Novartis AG |
Cell-based assay for measuring drug product potency
|
|
CN113528510A
(zh)
|
2018-06-29 |
2021-10-22 |
武汉纽福斯生物科技有限公司 |
治疗遗传性视神经病变的组合物和方法
|
|
SG11202101032VA
(en)
|
2018-08-20 |
2021-02-25 |
Wuhan Neurophth Biotechnology Ltd Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN120860258A
(zh)
*
|
2018-11-30 |
2025-10-31 |
北京诺华制药有限公司 |
Aav病毒载体及其用途
|
|
BR112021012104A2
(pt)
|
2018-12-18 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc. |
Métodos e composições para o tratamento de doenças de armazenamento de glicogênio
|
|
DK3906066T5
(da)
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
SG11202107645RA
(en)
*
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
MA56393A
(fr)
|
2019-06-28 |
2022-05-04 |
Bayer Healthcare Llc |
Matériels et méthodes de régulation de l'édition de gènes
|
|
EP4004213A1
(en)
|
2019-07-25 |
2022-06-01 |
Novartis AG |
Regulatable expression systems
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
US20230013253A1
(en)
|
2019-12-19 |
2023-01-19 |
Pfizer Inc. |
Compostions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
JP7703543B2
(ja)
|
2020-01-17 |
2025-07-07 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療
|
|
CN115210252A
(zh)
|
2020-02-04 |
2022-10-18 |
西雅图儿童医院（Dba西雅图儿童研究所） |
抗二硝基苯酚的嵌合抗原受体
|
|
JP2023514204A
(ja)
|
2020-02-14 |
2023-04-05 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
|
|
KR20220157944A
(ko)
|
2020-02-21 |
2022-11-29 |
아카우오스, 인크. |
인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
JP7526360B2
(ja)
*
|
2020-08-18 |
2024-07-31 |
ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． |
マルチモーダル金属アフィニティー処理ａａｖカプシド
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
|
EP4229204A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nucleic acid constructs for simultaneous gene activation
|
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
EP4508241A1
(en)
|
2022-04-13 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Method for determining aav genomes
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
CN119301260A
(zh)
|
2022-06-03 |
2025-01-10 |
豪夫迈·罗氏有限公司 |
用于生产重组aav颗粒的方法
|
|
KR20250036743A
(ko)
|
2022-07-14 |
2025-03-14 |
에프. 호프만-라 로슈 아게 |
재조합 aav 입자를 생산하는 방법
|
|
CA3264505A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES
|
|
AU2024216670A1
(en)
|
2023-02-07 |
2025-07-31 |
F. Hoffmann-La Roche Ag |
Method for the detection of anti-aav particle antibodies
|
|
EP4662231A1
(en)
|
2023-02-10 |
2025-12-17 |
Expression Therapeutics, LLC |
Lentiviral system
|
|
EP4669654A1
(en)
|
2023-02-22 |
2025-12-31 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Recombinant adeno-associated virus vectors lacking an immunodominant T-lymphocyte epitope and their use
|
|
WO2024196814A1
(en)
|
2023-03-17 |
2024-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treatment of age-related macular degeneration
|
|
AU2024239386A1
(en)
|
2023-03-21 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for the production of recombinant aav particle preparations
|
|
WO2025090942A1
(en)
*
|
2023-10-26 |
2025-05-01 |
University Of Notre Dame Du Lac |
Gene therapy for treatment of neurometabolic disease
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|
|
WO2026022064A1
(en)
|
2024-07-22 |
2026-01-29 |
F. Hoffmann-La Roche Ag |
Novel aav rep orfs and rep polypeptides
|
|
WO2026037757A1
(en)
|
2024-08-13 |
2026-02-19 |
F. Hoffmann-La Roche Ag |
Modified aav particles
|